SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL

• Published in: Hematological oncology Vol. 37; no. S2; pp. 132 - 134
• Main Authors: Nowakowski, G., Willenbacher, W., Greil, R., Larsen, T.S., Patel, K., Jäger, U., Manges, R.F., Trümper, L., Haioun, C., Everaus, H., Kalakonda, N., Knoble, J., Nully Brown, P., Jørgensen, J.M., Cunningham, D., Domper Rubio, N., Casadebaig, M., Manzke, O., Munoz, J.
• Format: Journal Article
• Language: English
• Published: Chichester Wiley Subscription Services, Inc 01.06.2019
• Subjects: Immunotherapy; Monoclonal antibodies; PD-L1 protein; Targeted cancer therapy